StreetAlpha.app
Home › Stocks › CADL

Candel Therapeutics, Inc. (CADL)

$5.40
▼ −7.06%
LAST CLOSE · NOV 17

Candel Therapeutics develops viral immunotherapies that are injected into tumors to fight cancer. It last closed at $5.40 on Nov 17, down 7.06% on the day. The average 12-month price target from 6 analysts is $18.83 (+248.8% from the last close), with a high of $25.00 and a low of $13.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (6 buy, 0 hold, 0 sell).

AI Auto Pilots
Is CADL in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$99.1M
EPS (diluted)
−$1.53
Free cash flow
−$70.2M
Valuation
Market cap
$423.6M
78.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$203.1M
At Sep 30
Shareholder equity
$131.6M
Shares outstanding
78.4M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$36.1M−$36.1MFY2021FY2022: −$18.8M−$18.8MFY2022FY2023: −$37.9M−$37.9MFY2023FY2024: −$55.2M−$55.2MFY2024FY2025: −$38.2M−$38.2MFY2025

From CADL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
6firms
6 Buy0 Hold0 Sell
Each firm's latest rating on CADL in the past 90 days
Average 12-month target
$18.83
▲ 248.8% upside

Based on 6 analysts who set a price target on CADL in the past 90 days. The average target is $18.83, with a high of $25.00 and a low of $13.00, compared with the last close of $5.40.

Low $13.00Avg $18.83High $25.00
Blue marker: last close $5.40
Highest target$25.00
Average target$18.83
Lowest target$13.00
Latest rating changes
CitigroupMaintained
Nov 16Buy$20
HC Wainwright & Co.Target lowered
Nov 13Buy$23 → $18
Canaccord GenuityMaintained
Nov 13Buy$13
StifelTarget lowered
Nov 13Buy$22 → $19
JefferiesInitiated
Oct 22Buy$25
DateFirmActionRatingPrice target
Nov 16CitigroupMaintainedBuy$20
Nov 13HC Wainwright & Co.Target loweredBuy$23 → $18
Nov 13Canaccord GenuityMaintainedBuy$13
Nov 13StifelTarget loweredBuy$22 → $19
Oct 22JefferiesInitiatedBuy$25
Loading…

Technical Analysis

CADL · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 51% below its 20 day and 75% below its 50 day average. It is 56% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the Pivot S1 at $5.15, and the nearest resistance the Pivot at $5.59.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 14.8%/day
Key levels
$14.0052 week high+159.3%
$10.25100 day average+89.8%
$9.4750 day average+75.4%
$8.93Swing high (Oct 29)+65.4%
$8.40200 day average+55.6%
$8.1620 day average+51.1%
$5.85Pivot R1+8.3%
$5.59Pivot+3.5%
$5.40Last close
$5.15Pivot S1−4.6%
$4.3552 week low−19.4%
Indicators
RSI (14)27.52Oversold below 30Oversold
MACD-0.76Below its signal lineBearish
Stochastic13.0Near the bottom of its rangeOversold
ADX (14)31.4Trending down
Williams %R-95.7Oversold below −80, overbought above −20Oversold
CCI (20)-234.1Oversold below −100, overbought above 100Oversold
Rate of change−38.8%Change over 10 sessionsBearish
ATR (14)$0.80Typical daily range, 14.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CADL

What happened before

See how CADL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CADL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CADL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in CADL in the last 90 days.

Loading…

See today’s whale options flow across the market →

CADL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲92 buying vs 42 selling
  • ▲Held by funds +0.7 pts
  • ▲Funds holding +3
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding141138+2.2%
In funds' top 10220.0%
Held by funds64.9%64.2%+0.7 pts
New / increased22 / 7040 / 62−9.8%
Reduced / sold out21 / 2123 / 13+16.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CADL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CADL is in one of them and how their past CADL trades turned out.

CADL in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CADL in an article yet. Here's the latest on the wider market.

About Candel Therapeutics

Candel Therapeutics is a clinical stage biopharmaceutical company based in Needham, Massachusetts. It develops viral immunotherapies for cancer, which are engineered viruses injected directly into tumors to stimulate the body's immune system against cancer. Its lead candidate, aglatimagene besadenovec, is being studied mainly for localized prostate cancer and for lung cancer. Its treatments are aimed at patients with a range of solid tumors.

Headquarters
Needham, MA